BRAF and glioblastoma: Taking all experimental results together, we found that primary glioblastoma cells with MGMT methylation, and IDH, TERT, or BRAF mutations, or 1p/19q co‐deletions were all sensitive to TEFT and showed no resistance compared to cells without any of the above 6 genetic traits.